Table 1 Transcription factors frequently changed in the nucleus of patients with AML FAB M1

From: Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

Gene symbol

Gene name

Frequency

Protein fold change (AML vs. CD34+)a

Normalized gene expression (fold change AML vs. CD34+)

NFIC

Nuclear Factor I C

6

5.5

1.5b

WT1

Wilms Tumor 1

8

2.9

5.6b

CEBPA

CCAAT/enhancer binding protein (C/EBP), alpha

7

2.9

1.7b

ILF3

Interleukin enhancer binding factor 3, 90 kDa

8

−2.4

−1.2

ILF2

Interleukin enhancer binding factor 2

7

−2.7

−1.2

hnRNPDL

Heterogeneous nuclear ribonucleoprotein D-like

11

−3.3

−1.0

BCL11A

B-cell CLL/lymphoma 11A (zinc finger protein)

8

−3.3

−1.4b

DAZAP1

TAR DNA-binding protein 43

10

−3.4

−1.2

TARDBP

DAZ associated protein 1

9

−3.8

1.3b

MYEF2

Myelin expression factor 2

10

−5.4

−3.7b

HMGA2

High mobility group AT-hook 2

14

−5.9

−3.0b

  1. Proteins were selected based on those that significantly changed co-directionally ± >2 fold between normal CD34+ control and AML in at least 5 of the 15 patients (frequency)
  2. aCalculation based solely on patients where a significant change was observed to derive the average fold change of AML vs. CD34+ normal control. Also shown are the fold changes of normalized gene expression data of corresponding mRNA. Positive values are upregulated in AML vs. control. Negative values downregulated in AML vs. control
  3. bGenes considered to have a change in mRNA transcript abundance when analyzed by ANOVA (P < 0.05) and ≥ ± 1.3 fold compared with control
Back to article page